Abstracts

Incidence and Outcome of HDV Infection in People With HIV in the Era of Tenofovir-Containing Therapy

Background: Tenofovir-containing antiretroviral therapy (ART) achieves high rates of HBV suppression and improves survival among HBV-infected people with HIV (PWH). We investigated the incidence of HDV infection among HBV-infected PWH and the impact of HDV on mortality and liver-related outcomes in the era of tenofovir-containing ART. Methods: HBV-infected PWH seeking HIV care at the National…

IL-21 Ameliorates Liver Inflammation by Enhancing MDSC Activity in Chronic HBV Infection

Background: In patients with chronic HBV infection, the immune response is inadequate for HBV clearance but can cause a persistent inflammatory reaction. Alleviating hepatitis may be possible by inhibiting the function of inflammatory cells during hepatitis activity. The potential for interleukin 21 (IL-21) to suppress liver inflammation by regulating the suppressive activity of myeloid-derived suppressor…

Hepatitis C Reinfection Among Men Who Have Sex With Men in an Acute HIV Cohort in Thailand

Background: The advent of direct-acting antivirals (DAAs) revolutionized the treatment of hepatitis C (HCV). However, HCV reinfections either after spontaneous clearance or sustained virologic response (SVR) pose a challenge in HCV elimination, particularly in high-risk populations. In this study, we determined the incidence and identified risk factors of HCV reinfection in a longitudinal early-treated acute…

Prevalence and Resistance Profiles of “Unusual” HCV Subtypes in Italy

Background: Recent data show that ‘unusual’ hepatitis C virus (HCV) subtypes have lower responses to direct-acting antivirals (DAAs) compared to most prevalent subtypes. We aimed to investigate the prevalence and resistance profiles of ‘unusual’ HCV subtypes in Italy. Methods: Clinical and virological data of ‘unusual’ HCV genotype (GT)/subtypes (defined as GT1 non-1a/b, GT2 non-2a/b, GT3…

Transfer of Sofosbuvir/Velpatasvir Into Breast Milk

Background: Treatment of hepatitis C virus in the postpartum period is delayed until after the completion of breastfeeding due to lack of data on infant exposure and safety. Our objectives were to describe breast milk transfer of sofosbuvir (SOF), GS-331007 (SOF inactive metabolite) and velpatasvir (VEL) in postpartum women being treated for HCV with SOF/VEL…